|
1
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Togashi Y, Masago K, Kubo T, Sakamori Y,
Kim YH, Hatachi Y, Fukuhara A, Mio T, Togashi K and Mishima M:
Association of diffuse, random pulmonary metastases, including
miliary metastases, with epidermal growth factor receptor mutations
in lung adenocarcinoma. Cancer. 117:819–825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu SG, Hu FC, Chang YL, Lee YC, Yu CJ,
Chang YC, Wu JY, Shih JY and Yang PC: Frequent EGFR mutations in
NSCLC presenting with miliary intrapulmonary carcinomatosis. Eur
Respir J. 41:417–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sekine A, Kato T, Hagiwara E, Shinohara T,
Komagata T, Iwasawa T, Satoh H, Tamura K, Kasamatsu T, Hayashihara
K, et al: Metastatic brain tumors from non-small cell lung cancer
with EGFR mutations: Distinguishing influence of exon 19 deletion
on radiographic features. Lung Cancer. 77:64–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mochizuki S, Nishimura N, Inoue A,
Murakami K, Nukiwa T and Chohnabayashi N: Miliary brain metastases
in 2 cases with advanced non-small cell lung cancer harboring EGFR
mutation during gefitinib treatment. Respir Investig. 50:117–121.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naidoo J, Sima CS, Rodriguez K, Busby N,
Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME and Yu HA:
Epidermal growth factor receptor exon 20 insertions in advanced
lung adenocarcinomas: Clinical outcomes and response to erlotinib.
Cancer. 121:3212–3220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noronha V, Choughule A, Patil VM, Joshi A,
Kumar R, Susan Joy, Philip D, Banavali S, Dutt A and Prabhash K:
Epidermal growth factor receptor exon 20 mutation in lung cancer:
Types, incidence, clinical features and impact on treatment. Onco
Targets Ther. 10:2903–2908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yasuda H, Kobayashi S and Costa DB: EGFR
exon 20 insertion mutations in non-small-cell lung cancer:
Preclinical data and clinical implications. Lancet Oncol.
13:e23–e31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Laack E, Simon R, Regier M, Andritzky B,
Tennstedt P, Habermann C, Verth CZ, Thöm I, Grob T, Sauter G and
Bokemeyer C: Miliary never-smoking adenocarcinoma of the lung:
Strong association with epidermal growth factor receptor exon 19
deletion. J Thorac Oncol. 6:199–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Falk AT, Poudenx M, Otto J, Ghalloussi H
and Barrière J: Adenocarcinoma of the lung with miliary brain and
pulmonary metastases with echinoderm microtubule-associated protein
like 4-anaplastic lymphoma kinase translocation treated with
crizotinib: A case report. Lung Cancer. 78:282–284. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dziadziuszko K, Szurowska E, Pienkowska J,
Jassem J and Dziadziuszko R: Miliary brain metastases in a patient
with ROS1-rearranged lung adenocarcin-oma: A case report. J Thorac
Oncol. 9:e34–e36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oxnard GR, Lo PC, Nishino M, Dahlberg SE,
Lindeman NI, Butaney M, Jackman DM, Johnson BE and Jänne PA:
Natural history and molecular characteristics of lung cancers
harboring EGFR exon 20 insertions. J Thorac Oncol. 8:179–184. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lund-Iversen M, Kleinberg L,
Fjellbirkeland L, Helland Å and Brustugun OT: Clinicopathological
characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J
Thorac Oncol. 7:1471–1473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang JC, Sequist LV, Geater SL, Tsai CM,
Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al:
Clinical activity of afatinib in patients with advanced
non-small-cell lung cancer harbouring uncommon EGFR mutations: A
combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 and LUX-Lung
6. Lancet Oncol. 16:830–838. 2015. View Article : Google Scholar : PubMed/NCBI
|
